Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
Key ADA poster summaries include liraglutide in type 1 diabetes, oral semaglutide, bottled water's association with type 2 diabetes, & SGLT-2 combo LIK066.
Read More »Poster Summaries of Interest at the 78th ADA Scientific Sessions
A Comparison of Safety and Efficacy of Semaglutide vs. Exenatide ER
GLP-1 agonists randomized showdown. Which agent is better?
Read More »Semaglutide Shows Superiority Over Exenatide ER in Head-to-Head Trial
Battle between two GLP-1 receptor agonists proves semaglutide achieves favorable HbA1c levels, decreased mean body weight.
Read More »Randomized Controlled Trials Vs. Effectiveness Of Real-World Use Of GLP-1’s and DPP4 Therapies
Why patients are not seeing results when it comes to adhering to treatment plans.
Read More »Safety and Efficacy of a New Long-Acting Exenatide Formulation: BYDUREON® BCise™
Once-weekly injectable suspension can provide as much benefit as traditional twice-daily dosing.
Read More »Semaglutide vs. Semaglutide in Treatment of Diabetes, Obesity
Study compares effectiveness of oral GLP-1 medication over injection.
Read More »Increased Quality of Life in Obesity and Prediabetes seen with Liraglutide
New study suggests improvement in quality of life and obesity seen with liraglutide compared with placebo.
Read More »Safety And Efficacy Of New Long-Acting Exenatide Formulation
Once-weekly exenatide formulation can provide as much benefit as the traditional twice-daily dosing.
Read More »Bydureon BCise: A New Once-Weekly GLP-1 Agonist
The FDA has approved an auto-injector and new formulation of a once-weekly treatment for type 2 diabetes from AstraZeneca. Bydureon BCise offers a single-dose auto-injector for adults with type 2 diabetes. Bydureon BCise features a unique continuous-release microsphere technology delivery system that provides consistent levels of the product’s active ingredient, exenatide. The new formulation has shown the ability to reduce blood sugar levels alongside weight loss, despite not being a weight loss medication.
Read More »Adding GLP-1 to Insulin
Patients with type 2 diabetes not responding to basal insulin therapy alone may see glycemic improvement with a GLP-1 receptor agonist.
Read More »